Company-reported prevalence
Dersimelagon
Overview
| Field | Value |
|---|---|
| Drug | Dersimelagon (MT-7117) |
| Indication | Erythropoietic protoporphyria or X-linked protoporphyria |
| Disease | Erythropoietic protoporphyria (EPP) |
| Company | Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation), developer, with its US subsidiary Tanabe Pharma America, Inc. (formerly Mitsubishi Tanabe Pharma America, Inc.); LEO Pharma A/S, worldwide rights acquired from Tanabe Pharma (agreement August 18, 2026; closing September 18, 2026) |
| Documents searched | Tanabe Pharma Corporation pipeline web page (accessed October 2026); Tanabe Pharma Corporation research and development news web page (accessed October 2026); Tanabe Pharma Corporation medical development web page (accessed October 2026); Tanabe Pharma Corporation Sustainability Report 2025; Tanabe Pharma Corporation press releases, January 15, 2026, March 30, 2026, August 18, 2026, and September 18, 2026; Mitsubishi Tanabe Pharma America press releases, March 19, 2024, and May 21, 2025; Tanabe Pharma America press releases, January 20, 2026, March 26, 2026, August 18, 2026, and September 18, 2026; Tanabe Pharma America science web page and community resources web page (accessed October 2026); LEO Pharma press release, August 18, 2026 (copy on the Nordic Capital website); LEO Pharma H1 2026 results press release, August 18, 2026; LEO Pharma Q2 2026 interim report, August 18, 2026; LEO Pharma press release, September 18, 2026; LEO Pharma pipeline web page (accessed October 2026) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
No evidence found.
Europe
Prevalence: Tanabe Pharma America press release, January 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Global
No evidence found.
Other countries and regions
No evidence found.
